Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

被引：0
作者：
Helen Dakin
Morris Sherman
Scott Fung
Carrie Fidler
Anthony Bentley
机构：
[1] Abacus International,Health Economics Research Centre, Department of Public Health
[2] University of Oxford,Department of Medicine
[3] University of Toronto and University Health Network,undefined
来源：
PharmacoEconomics | 2011年 / 29卷
关键词：
Lamivudine; Tenofovir; Adefovir; Tenofovir Disoproxil Fumarate; Entecavir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France. However, to our knowledge, no published studies have yet evaluated the cost effectiveness of any treatments for CHB in a Canadian setting, where relative prices and management of CHB differ from those in Europe.
引用
收藏
页码：1075 / 1091
页数：16
相关论文
共 124 条
[1]  
Wright TL(2006)Introduction to chronic hepatitis B infection Am J Gastroenterol 101 1-6
[2]  
Sherman M(2007)Management of chronic hepatitis B: consensus guidelines Can J Gastroenterol 21 5-24
[3]  
Shafran S(2004)Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206-17
[4]  
Burak K(1993)Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B: a meta-analysis Ann Intern Med 119 312-23
[5]  
Marcellin P(2009)EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227-42
[6]  
Lau GK(2003)Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 687-96
[7]  
Bonino F(2003)Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714-22
[8]  
Wong DK(2010)A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B Curr Hepat Rep 9 75-90
[9]  
Cheung AM(2009)Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 1503-14
[10]  
O’ Rourke K(2006)Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years Gastroenterology 131 1743-51
12345678910